LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

IVDR-Certified Mass Spectrometry Diagnostic System to Transform Detection of Monoclonal Gammopathies

By LabMedica International staff writers
Posted on 29 Aug 2023
Image: The IVDR-certified EXENT solution can transform diagnosis and monitoring of patients with monoclonal gammopathies (Photo courtesy of Thermo Fisher)
Image: The IVDR-certified EXENT solution can transform diagnosis and monitoring of patients with monoclonal gammopathies (Photo courtesy of Thermo Fisher)

Monoclonal gammopathies, including multiple myeloma, rank as the second most prevalent blood cancer globally, according to the 2020 report from the World Health Organization. Traditionally, treatment for these conditions involves monitoring M-protein levels, which can indicate the size of tumors. Despite significant treatment advancements, many patients are now achieving M-protein concentrations below detectable limits through standard methods. Yet, variations in disease progression persist within this patient group. Now, a new solution addresses this unmet clinical need for more sensitive analytical techniques that can differentiate between subsets of patients without resorting to invasive bone marrow biopsies prematurely.

Thermo Fisher Scientific (Waltham, MA, USA) has commercially launched the EXENT Solution after obtaining IVDR certification. This comprehensive and automated mass spectrometry system is designed to revolutionize diagnosis and assessment for individuals with monoclonal gammopathies. By utilizing the EXENT Solution, clinical laboratories can precisely measure, quantify, and monitor specific endogenous M-proteins and exogenous therapeutic monoclonal antibodies with heightened analytical sensitivity and precision in serum samples. The EXENT Solution has been developed to support the diagnosis of monoclonal gammopathies and facilitate the monitoring of patients with multiple myeloma and Waldenström's macroglobulinemia.

The EXENT Solution seamlessly integrates into routine laboratory workflows and comprises three integrated modules: EXENT-iP 500, an automated sample preparation instrument; EXENT-iX 500, a Matrix Assisted Laser Desorption Ionization - Time of Flight Mass Spectrometer (MALDI-ToF MS); and EXENT-iQ, an intelligent and user-friendly workflow software with data review capabilities. The system is complemented by the EXENT Immunoglobulin Isotypes (GAM) immunoassay, which is highly sensitive and specific for measuring and quantifying IgG, IgA, and IgM. The EXENT Solution is now available for commercial use in several countries, including Belgium, France, Germany, Italy, the Netherlands, Spain, and the United Kingdom.

“The EXENT Solution represents a significant breakthrough in innovation for the detection and monitoring of monoclonal immunoglobulins,” said Dr. Stephen Harding, Chief Scientific Officer, Protein Diagnostics, Thermo Fisher.

Related Links:
Thermo Fisher Scientific

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more